STOCK TITAN

Certara, Inc. SEC Filings

CERT Nasdaq

Welcome to our dedicated page for Certara SEC filings (Ticker: CERT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.

Problem: Certara’s model-informed drug development business packs pages of dense biosimulation jargon, multi-year SaaS contracts, and equity-based incentives into every disclosure. If you have ever searched for “Certara SEC filings explained simply” or tried to trace “Certara insider trading Form 4 transactions,” you know how time-consuming that can be.

Solution: Stock Titan’s AI reads each Certara annual report 10-K, Certara quarterly earnings report 10-Q filing, and Certara 8-K material events explained within minutes—so you don’t have to. Our platform delivers:

  • AI-powered summaries that translate technical pharmacokinetic language into plain English
  • Real-time alerts on Certara Form 4 insider transactions—never miss executive stock moves
  • Side-by-side earnings report filing analysis that highlights SaaS subscription growth, consulting margins, and backlog trends
  • Complete coverage of every form, from S-8 equity plans to the proxy statement executive compensation tables

Results: Monitor “Certara Form 4 insider transactions real-time,” compare revenue recognition notes across periods, or dive into “understanding Certara SEC documents with AI” in one workspace. Need governance details? Our tool surfaces board pay straight from the “Certara proxy statement executive compensation” section. Curious about future milestones? Material events in 8-K filings are flagged alongside modeling pipeline updates. Whether you are tracking “Certara earnings report filing analysis” before an FDA catalyst or auditing share repurchase disclosures, Stock Titan equips professionals with the clarity, speed, and confidence to act on Certara’s data-rich filings.

Rhea-AI Summary

Certara, Inc. is implementing a planned leadership transition, appointing Jon Resnick as Chief Executive Officer effective January 1, 2026, and as a Class III director with a term expiring at the 2026 annual meeting. He succeeds Dr. William F. Feehery, who will step down as CEO and director at the close of business on December 31, 2025 and then provide transition consulting services.

Under his employment agreement, Mr. Resnick will receive an initial annual base salary of $750,000, a target annual bonus equal to 100% of salary, a make-whole restricted stock unit grant valued at $6,500,000 vesting over the first two anniversaries of his start date, and long-term incentive awards targeted at $4,000,000 for 2025 and $8,000,000 for 2026, split 60% in performance-vesting units and 40% in time-vesting units. If his employment is terminated without cause or for good reason, he is eligible for cash severance of 1–1.5 times salary plus target bonus depending on change-in-control timing, pro-rated bonus, extended COBRA coverage, and specified accelerated equity vesting. Dr. Feehery’s departure will be treated as a termination without cause under his existing agreement, and he will receive $20,000 per month for consulting and pro-rata vesting of certain 2025 equity awards.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.06%
Tags
current report
-
Rhea-AI Summary

Certara (CERT) reported an insider buy by its CEO. William F. Feehery, who serves as Chief Executive Officer and Director, purchased 24,096.384 shares of Common Stock on 11/11/2025 at $8.3 per share (transaction code P). Following this transaction, his directly held stake stands at 2,360,769.384 shares.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
insider
-
Rhea-AI Summary

Certara, Inc. reported continued growth in Q3 2025. Revenue for the quarter reached $104.6 million, up from $94.8 million a year ago, and year‑to‑date revenue rose to $315.2 million from $284.8 million. The company posted quarterly net income of $1.5 million versus a loss last year, and year‑to‑date net income of $4.3 million compared with a prior-year loss. Gross cost trends remained controlled as operating expenses rose modestly alongside higher sales.

Cash generation strengthened and the balance sheet remained liquid. Cash and cash equivalents were $172.7 million as of September 30, 2025. Net cash provided by operating activities was $67.5 million year‑to‑date, more than double the prior year. Term loans stood at $296.3 million, with an effective rate of 7.39% year‑to‑date. The company executed share repurchases of $38.7 million in 2025, increasing treasury stock to 4,477,064 shares. Revenue mix showed software licenses and services both contributing, while deferred revenue was $65.9 million, supporting near‑term visibility. Interest rate risk is hedged with swaps totaling $230.0 million notional maturing in 2029.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.59%
Tags
quarterly report
Rhea-AI Summary

Certara, Inc. furnished an 8‑K to announce that it issued a press release with financial results for the three-month period ended September 30, 2025. The press release is attached as Exhibit 99.1.

The information provided under Item 2.02 (Results of Operations and Financial Condition), including Exhibit 99.1, is furnished and not deemed “filed” under Section 18 of the Exchange Act and is not incorporated by reference into other filings. The submission also includes Exhibit 104, the Cover Page Interactive Data File (Inline XBRL).

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.59%
Tags
current report
-
Rhea-AI Summary

Certara, Inc. amended its credit agreement on October 16, 2025, replacing its existing term loans with new Replacement Term Loans at lower pricing, which is expected to reduce borrowing costs and interest expense.

The loans now bear interest at the borrower’s election of Term SOFR (floor 0.00%) + 2.75% or an ABR (floor 1.00%) + 1.75%. ABR is the greatest of the prime rate, the federal funds effective rate + 0.50%, or Term SOFR + 1.00%. Proceeds were funded in full at closing and used to refinance the prior term loans. Guarantees, collateral, prepayments and covenants remain substantially similar.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
current report
-
Rhea-AI Summary

Dimensional Fund Advisors LP reported ownership of 8,352,281 shares of Certara Inc. common stock, representing 5.2% of the class as of 09/30/2025. The filing is a Schedule 13G, which indicates a passive investment approach rather than an active effort to influence control. Dimensional discloses it advises multiple Funds that collectively own the shares and expressly disclaims beneficial ownership while noting it has sole voting power over 8,244,677 shares and sole dispositive power over 8,352,281 shares. The signature certifies the holdings were acquired in the ordinary course of business.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
other
Rhea-AI Summary

Wasatch Advisors LP reported beneficial ownership of 17,398,337 common shares of Certara Inc, representing 10.8% of the class as of the filing event date. Wasatch holds sole dispositive power over all 17,398,337 shares and sole voting power over 12,631,748 shares. The filing identifies Wasatch as an investment adviser organized in Delaware and certifies the holdings were acquired and are held in the ordinary course of business and not for the purpose of changing control. The filing was signed by Wasatch CEO Mike Yeates on 10/07/2025 and lists Certara's principal executive office in Radnor, Pennsylvania.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
other
-
Rhea-AI Summary

Leif E. Pedersen, President and Chief Commercial Officer of Certara, Inc. (CERT), reported a sale of 51,224 shares of Certara common stock on 09/09/2025. The sales were effected under a Rule 10b5-1 trading plan adopted on March 5, 2025. The reported weighted-average sale price was $10.92, with individual trade prices ranging from $10.73 to $11.09. After the reported disposition, Mr. Pedersen beneficially owned 73,979 shares, reported as direct ownership. The Form 4 was signed by an attorney-in-fact on behalf of the reporting person.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
insider
-
Rhea-AI Summary

Form 144 filing for Certara, Inc. (CERT): The filer intends to sell 51,224 shares of common stock through Fidelity Brokerage Services on 09/09/2025, with an aggregate market value of $559,303.56. These shares represent restricted stock that vested on 09/09/2020 and were acquired as compensation from the issuer. The company reports 160,623,580 shares outstanding. The filer reports no sales of the issuer's securities in the past three months and includes the standard representation that they are not aware of any undisclosed material adverse information.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
other
Rhea-AI Summary

Wasatch Advisors LP reported beneficial ownership of 13,532,882 shares of Certara common stock, representing 8.3% of the class. The filer discloses sole dispositive power over all 13,532,882 shares and sole voting power on 9,969,332 shares, and states these securities are held in the ordinary course of business and not for the purpose of changing or influencing control.

This disclosure meets the >5% reporting threshold for institutional investors and notifies the market of a material passive stake in Certara without indicating any plans to seek control.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
other

FAQ

What is the current stock price of Certara (CERT)?

The current stock price of Certara (CERT) is $8.86 as of December 17, 2025.

What is the market cap of Certara (CERT)?

The market cap of Certara (CERT) is approximately 1.4B.
Certara, Inc.

Nasdaq:CERT

CERT Rankings

CERT Stock Data

1.38B
118.73M
2.51%
104.2%
8.37%
Health Information Services
Services-prepackaged Software
Link
United States
RADNOR